Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew W Roberts

Showing results (161-170 of 198) with videos related to

Pageof 20
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 26, 2006
Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 geneWarren S Alexander, Elizabeth M Viney, Jian-Guo Zhang, et al.
Blood|April 28, 2012
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsDelphine Mérino, Seong L Khaw, Stefan P Glaser, et al.
Cancer Research Communications|November 13, 2023
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 InhibitorsDennis Juarez, Roberta Buono, Shannon M Matulis, et al.
Blood|September 1, 2021
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLLPiers Blombery, Thomas E Lew, Michael A Dengler, et al.
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
Blood Advances|January 30, 2024
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, et al.
Blood|April 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissionsSasanka M Handunnetti, Mary Ann Anderson, Kate Burbury, et al.
Blood|July 28, 2018
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AMLMathijs A Sanders, Edward Chew, Christoffer Flensburg, et al.
The Lancet. Oncology|May 15, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
Internal Medicine Journal|January 12, 2017
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Constantine S Tam, Douglas Joshua, et al.
Pageof 20

Showing results (161-170 of 198) with videos related to

Sort By:
Pageof 20
Proceedings of the National Academy of Sciences of the United States of America|October 26, 2006
Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 geneWarren S Alexander, Elizabeth M Viney, Jian-Guo Zhang, et al.
Blood|April 28, 2012
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsDelphine Mérino, Seong L Khaw, Stefan P Glaser, et al.
Cancer Research Communications|November 13, 2023
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 InhibitorsDennis Juarez, Roberta Buono, Shannon M Matulis, et al.
Blood|September 1, 2021
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLLPiers Blombery, Thomas E Lew, Michael A Dengler, et al.
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
Blood Advances|January 30, 2024
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, et al.
Blood|April 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissionsSasanka M Handunnetti, Mary Ann Anderson, Kate Burbury, et al.
Blood|July 28, 2018
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AMLMathijs A Sanders, Edward Chew, Christoffer Flensburg, et al.
The Lancet. Oncology|May 15, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
Internal Medicine Journal|January 12, 2017
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Constantine S Tam, Douglas Joshua, et al.
Pageof 20